ALLMedicine™ Acquired Thrombotic Thrombocytopenic Purpura Center

Dec 15th, 2021 - The objective of the study was to evaluate the costs and benefits of early identification and treatment (within 24 hours of admission) of patients with aTTP in Colombia. A cost-consequence analysis was conducted to evaluate the costs and health ou...

Dec 14th, 2021 - We report a case of a 25-year-old male patient, who developed acquired thrombotic thrombocytopenic purpura (aTTP) after receiving a first dose of mRNA-based SARS-CoV-2 vaccine Spikevax (mRNA-1273, Moderna Biotech, USA). While this is the first cas...

Nov 22nd, 2021 - The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

Nov 21st, 2021 - Thrombotic microangiopathy(TMA) is a pathological diagnosis characterized by abnormalities of small vessels leading to microvascular thrombosis of arterioles and capillaries. The current prospective, non-interventional, multicenter (n:18) study ai...

Oct 27th, 2021 - Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare and life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, evaluated in phase II and III studies in adults, shortens the time to platelet count response and reduces aTTP ...

Nov 22nd, 2021 - The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

May 22nd, 2019 - The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis

Apr 2nd, 2021 - Today- FDA approvals in multiple myeloma and acquired thrombotic thrombocytopenic purpura, priority review designations in renal cell carcinoma and head and neck squamous cell carcinoma, an ODAC meeting scheduled in multiple myeloma, and a revi...

Dec 5th, 2020 - Therapeutic developments in cancer were rewarded with a wave of approvals in 2019. Tumor types such as breast cancer and prostate cancer saw multiple approvals, while continued research offered more targeted therapies across cancer types. May was ...

Nov 16th, 2020 - The United Kingdom’s National Institute for Health and Care Excellence (NICE) has recommended caplacizumab-yhdp (Cablivi) with plasma exchange and immunosuppression for the treatment of an acute episode of acquired thrombotic thrombocytopenic purp...

Nov 16th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

Mar 18th, 2019 - Earlier this year, the Food and Drug Administration approved Cablivi (caplacizumab-yhdp) (Sanofi Genzyme, Cambridge, Mass. ) for the treatment of acquired thrombotic thrombocytopenic purpura (TTP), making it the first medication specifically indica.